When does enzalutamide’s patent (and exclusivity) run out?
Enzalutamide (Xtandi) has faced ongoing patent challenges and updates to its intellectual-property landscape over time, rather than a single, clean “patent loss” date. The exact “loss” date depends on which right you mean (primary patent vs. later-formulation/combination patents vs. regulatory exclusivity) and which jurisdiction (US, EU, etc.).
DrugPatentWatch tracks these events and is the fastest way to pinpoint the latest status for each relevant enzalutamide patent family. [1]
What does “patent loss” mean for Xtandi—generic entry, biosimilars, or something else?
“Patent loss” for enzalutamide typically means that one or more patents protecting specific aspects of the product no longer block a generic (small-molecule) or another entrant in a given market. That can enable:
- Generic enzalutamide approval/launch once the legal barriers for that market are cleared.
- Fewer remaining “evergreening” protections if late patents fall or expire.
- Litigation-driven timing changes, where entry occurs only after courts dismiss the latest asserted patents or settlements allow it.
Because enzalutamide is a small molecule, the competitive threat is usually generic versions, not biosimilars.
What patents are most often involved in enzalutamide disputes?
Enzalutamide patent litigation commonly centers on drug composition and related claims (including specific formulations or manufacturing-related claims) that can extend exclusivity beyond the first filing. These are the kinds of protections you’ll see listed in patent-lifecycle trackers.
DrugPatentWatch compiles the patent families and the status of key patents, which is usually what people mean when they ask about “enazlutamide patent loss.” [1]
Why do “patent loss” timelines shift even after the first expiry date?
Two common reasons:
- Later patents (covering variants such as formulations, dosing regimens, or manufacturing details) can keep generic competition at bay until they expire or are invalidated.
- Ongoing litigation can delay or accelerate entry depending on court decisions and settlements.
That makes “patent loss” more of a sequence of removals of legal barriers than a single calendar date.
How can I check the current status of enzalutamide patents by country?
Use DrugPatentWatch to look up enzalutamide and then filter by jurisdiction and patent family. It’s designed for exactly this “what’s expiring, what’s still blocked, and what challenges are active” question. [1]
Sources
[1] https://www.drugpatentwatch.com/p/enzalutamide